- Laurus Labs reported a more than twofold increase in consolidated net profit to ₹361.99 crore (US$41.4 million) for the June quarter, with revenue rising 29% year over year to ₹2,026.31 crore (US$231.6 million).
- The company’s CDMO business grew 67% to ₹870 crore (US$99.4 million), led by strong demand for small molecule APIs, while the company also announced agreements to in-license two antibody-drug conjugates (ADCs).
Laurus Labs reported consolidated net profit of ₹361.99 crore (US$41.4 million) for the quarter ended June, more than doubling from the same period last year, as revenue from operations increased 29% year over year to ₹2,026.31 crore (US$231.6 million). The company’s performance was supported by growth in its CDMO and affordable medicines businesses.
Revenue from Laurus Labs’ CDMO business rose 67% year over year to ₹870 crore (US$99.4 million). Within the segment, small molecule revenue increased 69% to ₹835 crore (US$95.4 million), driven by late-stage clinical and commercial active pharmaceutical ingredient (API) supplies. Revenue from the bio (large molecules) business grew 21% to ₹35 crore (US$4.0 million). The results reflect continued growth in the company’s CDMO and contract manufacturing activities.
Executive Director and Chief Financial Officer V. V. Ravi Kumar said the company delivered a strong operating performance despite macroeconomic volatility. He added that momentum continued across both the CDMO and affordable medicines businesses, with EBITDA margin improving to 31.8% due to higher capacity utilization and operating leverage.
“Laurus Labs delivered record quarterly revenue while continuing its portfolio transformation. During the quarter, we also achieved important milestones, including agreement to in-license two antibody drug conjugates (ADCs) and securing final handover of land in Visakhapatnam for a new manufacturing facility, reinforcing our long-term growth strategy.”
Founder and Chief Executive Officer Satyanarayana Chava
The company said the agreements to in-license two ADCs and the acquisition of land in Visakhapatnam for a new manufacturing facility form part of its long-term growth strategy.
